Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort

HIV Medicine

Volumn 10, Issue 3, 2009, Pages 133-142

  Chaudhry, Amina A ^a   Sulkowski, M S ^a   Chander, G ^a   Moore, R D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alcohol; Aspartateamino transferase to platelet ratio index; Liver fibrosis; Viral hepatitis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT; URBAN POPULATION; VIRUS HEPATITIS; VIRUS TRANSMISSION; ALCOHOL LIVER CIRRHOSIS; BLOOD; COMPLICATION; ENZYMOLOGY; HEALTH; HEPATITIS B; HEPATITIS C; METABOLISM; PROGNOSIS; STATISTICAL MODEL;

ADULT; ALCOHOL-RELATED DISORDERS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LOGISTIC MODELS; MALE; PLATELET COUNT; PROGNOSIS; URBAN HEALTH;

EID: 61349155565     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00662.x     Document Type: Article

References (50)

1. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study. Arch Intern Med 2006; 166: 1632-1641.
2. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
3. Salmon-Ceron D, Lewden C, Morlat P et al. Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
4. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
5. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001; 16: 83-88.
6. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 2004; 28: 572-577.
7. Arnsten JH, Demas PA, Grant RW et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17: 377-381.
8. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19: 1111-1117.
9. Braithwaite RS, McGinnis KA, Conigliaro J et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol: Clin Exp Res 2005; 29: 1190-1197.
10. Chander G, Lau B, Moore RD. Hazardous alcohol use: A risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006; 43: 411-417.
11. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC. Veterans Aging Cohort 3-Site Study. How harmful is hazardous alcohol use and abuse in HIV infection: Do health care providers know who is at risk? J Acquir Immune Defic Syndr 2003; 33: 521-525.
12. Palepu A, Tyndall MW, Li K et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003; 80: 667-675.
13. Justice AC, Lasky E, McGinnis KA et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care 2006; 44 (Suppl. 2): S52-S60.
14. Kraemer KL, McGinnis KA, Skanderson M et al. Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care 2006; 44 (Suppl. 2): S44-S51.
15. Di Martino V, Rufat P, Boyer N et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199.
16. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000; 284: 450-456.
17. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA Cohort. AIDS 2005; 19: 593-601.
18. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: Interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36: 242-252.
19. Cooper CL, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 2005; 41 (Suppl. 1): S105-S109.
20. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
21. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
22. Poniachik J, Bernstein DE, Reddy KR et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996;43: 568-571.
23. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
24. Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA Index. J Hepatol 2005; 43: 78-84.
25. Lackner C, Struber G, Liegl B et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-1382.
26. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 (Suppl. 1): S38-S41.
27. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16: 767-774.
28. National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician's Guide, Updated 2005 edn. National Institute on Alcohol Abuse and Alcoholism, 2005. Available from: http://pubs.niaoa.nih.gov/publications/Practitioner/ CliniciansGuide2005/guide.pdf (last accessed 6 September 2008).
29. Castro KG, Ward JW, Slutsker L et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729-730.
30. Nunes D, Fleming C, Offner G et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40: 538-544.
31. Shastry L, Wilson T, Lascher S, Nord JA. The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients. AIDS 2007; 21: 2541-2543.
32. Snyder N, Gajula L, Xiao SY et al. APRI: An easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006; 40: 535-542.
33. Fabris C, Smirne C, Toniutto P et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to the platelet ratio index. Clin Biochem 2006; 39: 339-343.
34. Bourliere M, Penaranda G, Renou C et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: Proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670.
35. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6: 375-378.
36. Wai CT, Cheng CL, Wee A et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 666-672.
37. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101: 1500-1508.
38. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-1245.
39. Galvan FH, Bing EG, Fleishman JA et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV cost and services utilization study. J Stud Alcohol 2002; 63: 179-186.
40. Saitz R, Mulvey KP, Plough A, Samet JH. Physician unawareness of serious substance abuse. Am J Drug Alcohol Abuse 1997; 23: 343-354.
41. Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for alcohol problems: A meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction 2002; 97: 279-292.
42. Anton RF, O'Malley SS, Ciraulo DA et al. Combined pharmacotherapies and behavioral inAerventions for alcohol dependence: The COMBINE Study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
43. Aharonovich E, Hatzenbuehler ML, Johnston B et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care 2006; 18: 561-568.
44. Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
45. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 (Suppl. 1): S77-S84.
46. Latvala J, Parkkila S, Niemela O. Excess alcohol consumption is common in patients with cytopenia: Studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004; 28: 619-624.
47. Hietala J, Koivisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol and Alcoholism 2006; 41: 528-533.
48. Sloand E. Hematologic complications of HIV infection. AIDS Rev 2005; 7: 187-196.
49. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl. 1): S5-S10.
50. Mehta SH, Lucas GM, Mirel LB et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-2369.